cAMP stimulates the bystander effect in suicide gene therapy of human choriocarcinoma

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3411-3419

  Kunishige, Ichiro ^a   Samejima, Yoshihiro ^b   Moriyama, Akihiro ^a   Saji, Fumitaka ^b   Murata, Yuji ^c  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c NONE

Author keywords

8 bromo cAMP; Bystander effect; Choriocarcinoma; Gap junction; HSV tk

Indexed keywords

8 BROMO CYCLIC AMP; CYCLIC AMP; GANCICLOVIR; GAP JUNCTION PROTEIN; MESSENGER RNA; THYMIDINE KINASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANCER CELL CULTURE; CELL COMMUNICATION; CHORIOCARCINOMA; CONTROLLED STUDY; DNA TRANSFECTION; GAP JUNCTION; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SUICIDE GENE; TRANSCRIPTION REGULATION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; CELL COMMUNICATION; CELL SURVIVAL; CHORIOCARCINOMA; COMBINED MODALITY THERAPY; GANCICLOVIR; GENE THERAPY; HUMANS; PLASMIDS; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0031761173     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Vaccarello L, Apte SM, Diaz PT, Lewandowski GS and Copeland LJ: Respiratory failure from metastatic choriocarcinoma: A survivor of mechanical ventilation. Gynecol Oncol 67: 111-114, 1997.
2. Tham KF and Ratnam SS: Current views on the management of trophoblastic tumors. Int J Gynecol Obstet 49 (suppl): s77-s89, 1995.
3. Chen SH, Shine HD, Goodman JC, Grossman RG and Woo SL: Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 91: 3054-3057, 1994.
4. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS and Woo SL: Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 92: 2577-2581, 1995.
5. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B and Breakefield XO: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase. New Biol 3: 608-614, 1991.
6. Freeman SM, Whartenby KA, Koeplin DS, Moolten FL, Abboud CN and Abraham GN: Tumor regression when a fraction of tumor mass contains the HSV-tk gene. J Cell Biochem 16F: 47, 1992.
7. Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C and Marrogi A: The treatment of ovarian cancer with a gene modified cancer vaccine: A phase I study. Hum Gene Ther 6: 927-939, 1995.
8. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL and Anderson WT: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4: 39-69, 1993.
9. Moolten FL: Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1: 279-287, 1994.
10. Moolten FL and Wells M: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82: 297-300, 1990.
11. Matthews T and Boehme R: Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10: 490-494, 1988.
12. Barba D, Hardin J, Ray J and Gage FH: Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 79: 729-735, 1993.
13. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
14. Ram Z, Culver KW, Wallbridge S, Blaese RM and Oldfield EH: In SitU retroviral- mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53: 83-88, 1993.
15. Vrionis FD, Wu JK, Qi P, Cano WG and Cherington V: Tumor cells expressing the herpes simplex virus thymidine kinase gene in treatment of Walker 256 meningeal neoplasia in rats. J Neurosurg 84: 250-257, 1996.
16. Yoshimoto T, Yoshimoto E and Meruelo D: Identification of amino acid residues critical for infection with ecotropic murine leukemia retrovirus. J Virol 67: 1310-1314, 1993.
17. Instructions for use of Lipofectin reagent provided by manufacturer (GIBCO BRL, Gaithersburg, MD, USA).
18. Jimenez A and Davies J: Expression of a transposable antibiotic resistance element in Saccharomyces. Nature 287: 869-871, 1980.
19. Colbere-Garapin F, Horodniceanu F, Kourilsky P and Garapin AC: A new dominant hybrid selective marker for higher eukaryotic cells. J Mol biol 150: 1-14, 1981.
20. Haeflinger JA, Bruzzone R, Jenkins NA, Gilbert DJ, Copeland NG and Paul DL: Four novel members of the connexin family of gap junctions. J Biol Chem 267: 2057-2064, 1992.
21. El-Fouly MH, Trosko JE and Chang CC: Scrape-loading and dye transfer. A rapid and simple technique to study gap junctional intercellular communication. Exp Cell Res 168: 422-430, 1987.
22. Pepper MS, Montesano R, el-Aoumari A, Gros D, Orci L and Meda P: Coupling and connexin 43 expression in microvascular and large vessel endothelial cells. Am J Physiol 262: 1246-1257, 1992.
23. Culver KW and Blaese RM: Gene therapy for cancer. Trends Genet 10: 174-178, 1994.
24. Kuriyama S, Nakatani T, Masui K, Sakamoto T, Tominaga K, Yoshikawa M, Fukui H, Ikenaka K and Tsuji T: Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma. Hepatology 22: 1838-1846. 1995.
25. Yoshida K, Kawai H, Yamaguchi Y, Kuniyasu H, Nishiyama M, Hirai T, Yanagihara K, Tahara E, and Toge T: Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene. Cancer 75: 1467-1471, 1995.
26. Nielsen CS, Moorman DW, Levy JP and Link CJ Jr: Herpes simplex thymidine kinase gene transfer is required for complete regression of murine colon adenocarcinoma. Am Surg 63: 617-620, 1997.
27. Dilber MS, Abedi MR, Bjorkstrand B, Christensson B, Gahrton G, Xanthopoulos KG and Smith CI: Suicide gene therapy for plasma cell tumors. Blood 88: 2192-2200, 1996.
28. Hasegawa Y, Emi N and Shimokata K: Retroviral transfer of HSV 1-TK gene into human lung cancer cell line. J Mol Med 73: 107-112, 1995.
29. Tong XW, Block A, Chen SH, Woo SLC and Kieback DG: Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Anticancer Res 16: 1611-1618, 1996.
30. Rosenfeld ME, Wang M, Siegal GP, Alvarez RD, Mikheeva G, Krasnykh V and Curiel DT: Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in SCID mouse model of human ovarian carcinoma. J Mol Med 74: 455-462, 1996.
31. Tong XW, Block A, Chen SH, Contant CF, Agoulnik I, Blankenburg K, Kaufman RH, Woo SLC and Kieback DG: In vivo gene therapy of ovarian cancer by adenovirus- mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol 61: 175-179, 1996.
32. Al-Hendy A and Auersperg N: Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: An effective in vitro drug-sensitization system. Gynecol Obstet Invest 43: 268-275, 1997.
33. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993.
34. Qian C, Bilbao R, Bruna O and Prieto J: Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of helpe. simplex virus thymidine kinase. Hepatology 22: 118-123, 1995.
35. Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DG and Blaese RM: Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Therapy 4: 244-251, 1997.
36. Vrionis FD, Wu JK, Qi P, Cano W, Cherington V: A more potent bystander cytocidal effect elicitedby tumor cells expressing the herpes simplex virus-thymidine kinase gene than by fibroblast virus-producer cells in vitro. J Neurosurg 83: 698-704, 1995.
37. Barba D, Hardin J, Sadelain M and Gage FH: Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 91: 4348-4352, 1994.
38. Bi WL, Parysek LM, Warnick R and Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 4: 725-731, 1993.
39. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D: Regression of established macroscopic liver metastasis after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90: 7024-7028, 1993.
40. Tapscott SJ, Miller AD, Olson JM, Berger MS, Groudine M and Spence AM: Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable gene does not require drug selection. Proc Natl Acad Sci USA 91: 8185-8189, 1994.
41. Fick J, Barker FG 2nd, Dazin P, Westphale EM, Beyer EC and Israel MA: The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxity In vitro. Proc Natl Acad Sci USA 92: 11071-11075, 1995.
42. Mesnil M, Piccoli C, Tiraby G, Willecke K and Yamasaki H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93: 1831-1835, 1996.
43. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR and Albelda SM: Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 3: 85-92, 1996.
44. Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CC, Gahrton G and Smith CI: Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 57: 1523-1528, 1997.
45. Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V and Spray DC: The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Therapy 4: 577-585, 1997.
46. Bennett MVL, Barrio LC, Bargiello TA, Spray DC, Hertzberg E and Saez JC: Gap junctions: New tools, new answers, new questions (review). Neuron 6: 305-320, 1991.
47. Pitts JD: Cancer gene therapy: A bystander effect using the gap junctional pathway. Mol Carcinog 11: 127-130, 1994.
48. Spray DC and Dermietzel R: X-linked Charcot-Marie-Tooth disease and other potential gap junction diseases of the nervous system. Trends Neurosci 18: 256-262, 1995.
49. Yamasaki H: Gap junctional intercellular communication and carcinogenesis. Carcinogenesis 11: 1051-1058, 1990.
50. Willecke K: the mouse connexin gene family. In: Hall JE, Zampighi GA, Davis M (eds) Progress in cell research, vol 4. Elserier, Amsterdam, pp33-37.
51. Willecke K, Hennemann H, Dahl E, Jungbluth S and Heynkes R: The diversity of connexin genes encoding gap junctional proteins. Eur J Cell Biol 56: 1-7, 1991.
52. Mesnil M, Piccoli C and Yamasaki H: A tumor suppressor gene, Cx 26, also mediates the bystander effect in Hela cells. Cancer Res 57: 2929-2932, 1997.
53. Mehta PP, Yamamoto M and Rose B: Transcription of the gene for the gap junctional protein connexin 43 and expression of functional cell-to-cell channels are regulated by cAMP. Mol Biol Cell 3: 839-850, 1992.
54. Schiller PC, Mehta PP, Roos BA and Howard GA: Hormonal regulation of intercellular communication: Parathyroid hormone increases connexin 43 gene expression and gapjunctional communication in osteoblastic cells. Mol Endocrinol 6: 1433-1440, 1992.
55. Chiba H, Sawada N, Oyamada M, Kojima T, Iba K, Ishii S and Mori M: Hormonal regulation of connexin 43 expression and gap junctional communication in human osteoblastic cells. Cell Struct Funct 19: 173-177, 1994.
56. Hellmann P, Von Ostau C, Grummer R and Winterhager E: Connexin 40 expression in the human trophoblast: implication for proliferation and invasion properties. Placenta 16: A26, 1995.
57. Hellmann P, Winterhager E and Spray DC: Properties of connexin 40 gap junction channels endogeneously expressed and exogeneously overexpressed in human choriocarcinoma cell lines. Pflugers Arch-Eur J Physiol 432: 501-509, 1996.
58. Darrow BJ, Fast VG, Kleber AG, Beyer EC and Staffitz JE: Functional and structural assessment of intercellular communication. Increased conduction velocity and enhanced connexin expression in dibutyryl cAMP-treated cultured cardiac myocytes. Circ Res 79: 174-183, 1996.
59. Yu W, Dahl G and Werner R: The connexin43 gene is responsive to oestrogen. Proc R Soc Lond (Biol) 255: 125-132, 1994.